John B.A.G. Haanen, MD, PhD, on Melanoma: Phase III Data on Treatment With Tumor-Infiltrating Lymphocytes vs Ipilimumab
ESMO Congress 2022
John B.A.G. Haanen, MD, PhD, of The Netherlands Cancer Institute, discusses recent phase III findings, which show that tumor-infiltrating lymphocytes (TILs) improve progression-free survival compared with ipilimumab by 50% in patients with advanced melanoma after not responding to anti–PD-1 treatment. Around 50% of TIL-treated patients had a response, and 20% had a complete response (Abstract LBA3).
Transcript
Disclaimer: This video transcript has not been proofread or edited and may contain errors.
At the ESMO Congress, I presented the results from the randomized controlled phase three trial comparing infusion with tumor infant lymphocytes to ipilimumab in patients with metastatic melanoma. The trial was designed for patients with cutaneous melanoma having failed at the maximum of one prior treatment. The majority, meaning almost 90% of the patients, had received prior anti PD one treatment when they went on the trial. Patients were randomized to receive either TIL treatment or ipilimumab. In total, 168 patients were randomized one to one, and the primary endpoint of the study was progression free survival by investigative review in the intention to treat population.
The results from this trial show a 50% reduction in risk of progression or death, in favor of the TIL treatment compared to ipilimumab. The median progression for survival for the TIL treat patients was 7.2 months compared to a 3.1 months for patients treated with ipilimumab.
When we look at the overall response rates, TIL compared much better than ipilimumab. We saw a 49% overall response rate for the TIL treat patients, 20% having complete remission. This compared to 21% for [inaudible 00:01:34] treated patients with 7% complete remission.
We did look at the overall survival and there was a trend for better overall survival for patients treated with TIL. However the study was not powered to show this overall survival. The median overall survival for the TIL treated patients was over 25 months compared to over 18 months. Therefore, the ipilimumab treated patients.
Side effects occurred in both treatment arms in all patients received that received TIL treatment. They had a grade three or higher adverse events. These adverse events could be attributed to the lymph repeating chemotherapy consisting of cyclophosphamide and [inaudible 00:02:16] or the high dose interleukin-2 that these patient received following TIL infusion.
These side effects had completely disappeared by the time the patients were released from the hospital, and there were no long term problems seen in these patients due to side effects. Also, health related quality of life, scores were better in patients treated with TIL compared to ipi, and this was maximum around 18 weeks after treatment. It was still visible at around one year after treatment.
So in conclusion, this is the first randomized control trial with a cell therapy in a solid cancer. In this case, treatment with TIL compared to ipilimumab for patient with advanced melanoma. And there was a clear difference in progression for survival and overall response rate in favor of the TIL treated patients and their side effects were manageable, and health related quality of life was better for the TIL treated patients.
So we think that TIL therapy could become a new treatment option for patients with metastatic melanoma. In future research, we will look at the infusion products, and also look for correlations between the cells in these infusion products and outcome. And hopefully we will be able to share those results at a later time point.
Related Videos
The ASCO Post Staff
Sapna P. Patel, MD, of The University of Texas MD Anderson Cancer Center, discusses the latest findings from the SWOG S1801 trial, which showed that using single-agent pembrolizumab as neoadjuvant therapy improved event-free survival compared to adjuvant therapy in high-risk resectable stage III–IV melanoma (Abstract LBA6).
The ASCO Post Staff
Toni K. Choueiri, MD, of the Dana-Farber Cancer Institute, and Laurence Albiges, MD, PhD, of France’s Gustave Roussy Cancer Centre, discuss phase III findings showing that cabozantinib in combination with nivolumab and ipilimumab reduced the risk of disease progression or death compared with the combination of nivolumab plus ipilimumab in patients with previously untreated advanced renal cell carcinoma of IMDC (the International Metastatic RCC Database Consortium) intermediate or poor risk. However, the combination of cabozantinib, nivolumab, and ipilimumab vs nivolumab plus ipilimumab did not demonstrate an overall survival benefit to patients (Abstract LBA8).
The ASCO Post Staff
Toni K. Choueiri, MD, of the Dana-Farber Cancer Institute, and Laurence Albiges, MD, PhD, of France’s Gustave Roussy Cancer Centre, discuss results from two important trials presented at ESMO 2022: Cohort 1 of the LITESPARK-003 study of belzutifan plus cabozantinib as first-line treatment of advanced renal cell carcinoma (RCC), and the KEYNOTE-B61 study of pembrolizumab plus lenvatinib as first-line treatment for non–clear cell RCC (Abstracts 1447O and 1448O).
The ASCO Post Staff
Christelle de la Fouchardiere, MD, of France’s Centre Léon Bérard, discusses phase III findings from the PRODIGE 65–UCGI 36–GEMPAX UNICANCER study, which evaluated whether the combination of gemcitabine and paclitaxel improves overall survival compared with gemcitabine alone in patients with metastatic pancreatic ductal adenocarcinoma after FOLFIRINOX failure or intolerance (Abstract LBA60).
The ASCO Post Staff
Marleen Kok, MD, PhD, of The Netherlands Cancer Institute in Amsterdam, discusses the initial results from the BELLINI trial, which tested whether short-term preoperative nivolumab, either as monotherapy or in combination with low-dose doxorubicin or novel immunotherapy combinations, can induce immune activation in patients with early-stage triple-negative breast cancer with tumor-infiltrating lymphocytes (Abstract LBA13).
